Afficher la notice abrégée

Health state utility and quality of life measures in patients with chronic myeloid leukemia in France

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFOULON, S
dc.contributor.authorCONY-MAKHOUL, P
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGUERCI-BRESLER, A
dc.contributor.authorDABAN, M
dc.contributor.authorKAPSO, R
dc.contributor.authorTUBERT-BITTER, P
dc.contributor.authorBONASTRE, J
dc.date.accessioned2021-04-26T14:47:56Z
dc.date.available2021-04-26T14:47:56Z
dc.date.issued2021-03-02
dc.identifier.issn0962-9343en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/27109
dc.description.abstractEnPURPOSE: Tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of chronic myeloid leukemia (CML). We aimed to assess health state utility and quality of life (QoL) in French patients with CML in real-life setting, to study the determinants of utility score and to compare health-related QoL values to general population norms. METHODS: We conducted a cross-sectional study in 412 patients with CML. Data were collected by electronic survey. Three patient-reported outcomes questionnaires were used: EORTC QLQ-C30, EORTC QLQ-CML24 and EuroQol EQ-5D-3L. Health state utility values were computed using the French value set. We computed deviations from reference norms from the general population. We studied the determinants of health utility score using multiple regression models. RESULTS: The mean utility score (SD) was 0.72 (0.25) in the chronic phase and 0.84 (0.21) in treatment-free remission, with marked variations by gender. Patients with CML had a deviation from the reference norm of -0.15 on average (SD: 0.25). In terms of QoL, social functioning, role functioning and cognitive functioning were notably impacted with a mean difference of -16.0, -13.1 and -11.7 respectively. Fatigue, dyspnea and pain were the symptoms with the highest deviation from general population norms (mean difference of 20.6, 14.0 and 8.3 respectively). In the multiple regression analysis, fatigue was the most important independent predictor of the utility score. CONCLUSION: Although TKIs prevent the disease from progressing and even allow remission without treatment, QoL in patients with CML is notably altered. The utility scores deteriorate with CML symptoms.
dc.description.sponsorshipInstitut de Médecine Personnalisée du Cancer - ANR-10-IBHU-0001en_US
dc.language.isoENen_US
dc.subject.enChronic myeloid leukemia
dc.subject.enQuality of life
dc.subject.enTyrosine kinase inhibitor
dc.subject.enHealth utility score
dc.title.enHealth state utility and quality of life measures in patients with chronic myeloid leukemia in France
dc.title.alternativeQual Life Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s11136-021-02794-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33651280en_US
bordeaux.journalQuality of Life Researchen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03208632
hal.version1
hal.date.transferred2021-04-26T14:48:00Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Quality%20of%20Life%20Research&rft.date=2021-03-02&rft.eissn=0962-9343&rft.issn=0962-9343&rft.au=FOULON,%20S&CONY-MAKHOUL,%20P&GUERCI-BRESLER,%20A&DABAN,%20M&KAPSO,%20R&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée